share_log
Reuters ·  Mar 26 11:05
Viking Therapeutics Announces Completion of Enrollment in Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 343

Recommended

Write a comment